Taken separately, each component of the Medtronic integrated system may help reduce your HbA1c 1,2,3, provide a more complete picture of your diabetes therapy, and help you gain tighter control. Together, our exceptional components add up to the most integrated diabetes management system on the planet.3
Exceptional Components
1 Unparalleled Diabetes Management System
The Paradigm™ Veo™ Insulin Pump Meet the cornerstone of your new diabetes management system:
The Paradigm™ Veo™ Insulin Pump.
This small, portable device fits easily into your lifestyle, continuously delivering fast-acting insulin 24 hours a day. It’s easy to operate and gives you a whole new level of flexibility, allowing you to sleep in, eat and exercise when you want.The Paradigm™ Veo™ Insulin Pump.
Advanced, Precise Insulin Delivery
With customisable basal patterns, the Paradigm™ Veo™ Insulin Pump can accommodate your changing daily lifestyle and body needs, such as weekday schedules, weekend activities and illnesses.
The Paradigm™ Veo™ Insulin Pump includes:
The Medtronic Bolus Wizard™ Calculator, Three Bolus Options, Active Insulin Onboard display, a Missed Meal Bolus reminder, and numerous other features, for more information click here.
The Medtronic Bolus Wizard™ Calculator, Three Bolus Options, Active Insulin Onboard display, a Missed Meal Bolus reminder, and numerous other features, for more information click here.
Take control to the next level by adding
REAL-Time Continuous Glucose Monitoring (CGM) to your insulin pump.
Successful diabetes management is not just about knowing where you are… it’s about knowing where you’ve been and where you’re going.
Only the Medtronic Diabetes Paradigm™ REAL-Time System and the new Paradigm™ Veo™ System offer continuous glucose monitoring right on your insulin pump. This integrated approach takes diabetes management to a level you may not achieve with other insulin pumps. Fingerstick testing is useful, but it only gives you a blood glucose reading for a particular moment in time. It may not allow you to readily identify your glucose trends. Fingerstick tests are like watching only a few scenes; CGM is like watching an entire movie. You get the full story. To learn more about CGM, click here.
In a world first and taking diabetes management to a new level, the Paradigm™ Veo™ insulin pump with Continuous Glucose Monitoring is equipped with a Low Glucose Suspend (LGS) mechanism. To learn more about LGS, click here.
The CGM feature is an optional extra and can be switched on or off depending on your needs – now and in the future.
Technology, meet life.Medtronic CareLink® Personal Software is a free, web-based tool that may help you optimise your insulin pump therapy and glucose control.3
The more you know, the more you can do. Understanding the effects of insulin dosage, eating habits, exercise routine, and medication on glucose levels plays an important role in improving your diabetes control. Seeing this cause-and-effect relationship in chart, graph, and table formats allows you to better identify patterns and problems that may help you to figure out the cause of your low and high glucose levels. With Medtronic CareLink® Personal Software, you are empowered to optimise your therapy by working with your Healthcare Provider to reach your individual
goals. For more information on Medtronic CareLink® Personal Software,
click here. 
To download further information (user guides, fact sheets,
etc), please click
here.
To access the ParadigmTM VeoTM tutorial, click
here.
1. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes:
meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765-774.
2. Deiss D, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730-32.
3. Corriveau EA, et al. Effect of Carelink, an internet-based insulin pump monitoring system, on glycemic control in rural and urban children with type 1 diabetes mellitus. Pediatric Diabetes. 2008;9(Part ii):360-366.
4. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 1993;329(14):977-986.
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEJM. 2005;353(25):2643-2653.
2. Deiss D, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730-32.
3. Corriveau EA, et al. Effect of Carelink, an internet-based insulin pump monitoring system, on glycemic control in rural and urban children with type 1 diabetes mellitus. Pediatric Diabetes. 2008;9(Part ii):360-366.
4. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 1993;329(14):977-986.
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEJM. 2005;353(25):2643-2653.
